SCILEX HOLDING CO (SCLX)
US80880W1062 - Common Stock
SCLX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. SCLX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, SCLX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
SCLX had negative earnings in the past year.
In the past year SCLX has reported a negative cash flow from operations.
1.2 Ratios
SCLX has a Return On Assets of -164.82%. This is amonst the worse of the industry: SCLX underperforms 89.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -164.82% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-63.75%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SCLX has a better Gross Margin (66.45%) than 70.26% of its industry peers.
SCLX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.45% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SCLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SCLX has been reduced compared to 1 year ago.
The debt/assets ratio for SCLX is higher compared to a year ago.
2.2 Solvency
SCLX has an Altman-Z score of -11.85. This is a bad value and indicates that SCLX is not financially healthy and even has some risk of bankruptcy.
SCLX has a Altman-Z score of -11.85. This is in the lower half of the industry: SCLX underperforms 78.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.85 |
ROIC/WACCN/A
WACC8.22%
2.3 Liquidity
SCLX has a Current Ratio of 0.19. This is a bad value and indicates that SCLX is not financially healthy enough and could expect problems in meeting its short term obligations.
SCLX's Current ratio of 0.19 is on the low side compared to the rest of the industry. SCLX is outperformed by 98.46% of its industry peers.
A Quick Ratio of 0.17 indicates that SCLX may have some problems paying its short term obligations.
SCLX has a Quick ratio of 0.17. This is amonst the worse of the industry: SCLX underperforms 97.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.19 | ||
| Quick Ratio | 0.17 |
3. Growth
3.1 Past
SCLX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1838.18%.
SCLX shows a strong growth in Revenue. In the last year, the Revenue has grown by 292.17%.
EPS 1Y (TTM)-1838.18%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-74.16%
Revenue 1Y (TTM)292.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q12.95%
3.2 Future
Based on estimates for the next years, SCLX will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.20% on average per year.
The Revenue is expected to grow by 37.53% on average over the next years. This is a very strong growth
EPS Next Y35.5%
EPS Next 2Y11.36%
EPS Next 3Y17.2%
EPS Next 5YN/A
Revenue Next Year94.57%
Revenue Next 2Y62.72%
Revenue Next 3Y39.46%
Revenue Next 5Y37.53%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SCLX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SCLX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SCLX's earnings are expected to grow with 17.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.36%
EPS Next 3Y17.2%
5. Dividend
5.1 Amount
SCLX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SCILEX HOLDING CO
NASDAQ:SCLX (5/9/2024, 7:17:32 PM)
After market: 0.84 +0.01 (+1.18%)0.8302
-0.02 (-2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap137.97M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -164.82% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.45% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.19 | ||
| Quick Ratio | 0.17 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-1838.18%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y35.5%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)292.17%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y